Výsledky vyhľadávania - "Trastuzumab"

Medical Management of an Infusion Site Extravasation Injury After Peripheral Intravenous Infusion of Ado-Trastuzumab Emtansine in a 38-Year-Old Woman with Breast Cancer: A Case Report.

Autori: Gamvroulas EM Jeppson P Wei M

Zdroj: The American journal of case reports [Am J Case Rep] 2025 Oct 24; Vol. 26, pp. e949828. Date of Electronic Publication: 2025 Oct 24.

Spôsob vydávania: Journal Article; Case Reports

Informácie o časopise: Publisher: International Scientific Information, Inc Country of Publication: United States NLM ID: 101489566 Publication Model: Electronic Cited Medium: Internet ISSN: 1941-5923 (Electronic) Linking ISSN: 19415923 NLM ISO Abbreviation: Am J Case Rep Subsets: MEDLINE

Výrazy zo slovníka MeSH: Ado-Trastuzumab Emtansine*/adverse effects , Ado-Trastuzumab Emtansine*/administration & dosage , Breast Neoplasms*/drug therapy , Antineoplastic Agents, Immunological*/adverse effects , Antineoplastic Agents, Immunological*/administration & dosage , Extravasation of Diagnostic and Therapeutic Materials*/etiology , Extravasation of Diagnostic and Therapeutic Materials*/drug therapy , Maytansine*/analogs & derivatives , Maytansine*/adverse effects , Maytansine*/administration & dosage, Humans ; Female ; Adult ; Infusions, Intravenous/adverse effects ; Trastuzumab/adverse effects ; Trastuzumab/administration & dosage

Neoadjuvant Regimens and Their Impact on Adjuvant T-DM1 Outcomes in HER2-Positive Early Breast Cancer.

Autori: Agaoglu AB Erdogan AP Ekinci F a ďalší

Zdroj: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2025 Nov 01; Vol. 61 (11). Date of Electronic Publication: 2025 Nov 01.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE

Výrazy zo slovníka MeSH: Breast Neoplasms*/drug therapy , Neoadjuvant Therapy*/methods , Ado-Trastuzumab Emtansine*/therapeutic use, Humans ; Female ; Middle Aged ; Adult ; Retrospective Studies ; Receptor, ErbB-2/analysis ; Trastuzumab/therapeutic use ; Chemotherapy, Adjuvant/methods ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Paclitaxel/therapeutic use ; Docetaxel/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Treatment Outcome

Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study.

Autori: Akturk Esen S Seven I Akdere Ates G a ďalší

Zdroj: Anti-cancer drugs [Anticancer Drugs] 2025 Aug 01; Vol. 36 (7), pp. 575-582. Date of Electronic Publication: 2025 Apr 01.

Spôsob vydávania: Journal Article; Multicenter Study

Informácie o časopise: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE

Výrazy zo slovníka MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Receptor, ErbB-2*/metabolism , Ado-Trastuzumab Emtansine*/therapeutic use , Ado-Trastuzumab Emtansine*/adverse effects , Ado-Trastuzumab Emtansine*/administration & dosage , Antineoplastic Agents, Immunological*/therapeutic use , Antineoplastic Agents, Immunological*/adverse effects , Antineoplastic Agents, Immunological*/administration & dosage, Humans ; Female ; Middle Aged ; Chemotherapy, Adjuvant ; Retrospective Studies ; Turkey ; Adult ; Aged ; Neoadjuvant Therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasm Staging ; Trastuzumab/administration & dosage ; Survival Rate ; Disease-Free Survival

Reliable Quantification of Conjugated Peptides from T-DM1 In Vivo by Two-Step Enrichment and Internal Standards from Derivatized Analytes.

Autori: Qi M Xiong Y Chen M a ďalší

Zdroj: Analytical chemistry [Anal Chem] 2025 Jul 01; Vol. 97 (25), pp. 13522-13531. Date of Electronic Publication: 2025 Jun 17.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: American Chemical Society Country of Publication: United States NLM ID: 0370536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-6882 (Electronic) Linking ISSN: 00032700 NLM ISO Abbreviation: Anal Chem Subsets: MEDLINE

Výrazy zo slovníka MeSH: Peptides*/blood , Peptides*/chemistry , Peptides*/analysis , Maytansine*/analogs & derivatives , Maytansine*/chemistry , Maytansine*/blood , Trastuzumab*/chemistry , Trastuzumab*/blood , Immunoconjugates*/chemistry , Immunoconjugates*/blood, Animals ; Ado-Trastuzumab Emtansine ; Rats ; Chromatography, Liquid ; Rats, Sprague-Dawley ; Tandem Mass Spectrometry ; Reference Standards ; Male

Successful Neoadjuvant Treatment Using Trastuzumab Emtansine (Kadcyla) for Locally Advanced and Metastatic Lacrimal Gland Adenocarcinoma.

Autori: Kakouri A Debnam MJ Ferrarotto R a ďalší

Zdroj: Ophthalmic plastic and reconstructive surgery [Ophthalmic Plast Reconstr Surg] 2025 Sep-Oct 01; Vol. 41 (5), pp. e183-e187. Date of Electronic Publication: 2025 May 07.

Spôsob vydávania: Journal Article; Case Reports

Informácie o časopise: Publisher: Lippincott Williams & Wilkins for the American Society of Ophthalmic Plastic and Reconstructive Surgery Country of Publication: United States NLM ID: 8508431 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-2677 (Electronic) Linking ISSN: 07409303 NLM ISO Abbreviation: Ophthalmic Plast Reconstr Surg Subsets: MEDLINE

Výrazy zo slovníka MeSH: Adenocarcinoma*/drug therapy , Adenocarcinoma*/secondary , Lacrimal Apparatus Diseases*/drug therapy , Lacrimal Apparatus Diseases*/pathology , Lacrimal Apparatus Diseases*/diagnosis , Antineoplastic Agents, Immunological*/therapeutic use , Trastuzumab*/therapeutic use , Eye Neoplasms*/drug therapy , Eye Neoplasms*/pathology , Maytansine*/analogs & derivatives , Maytansine*/therapeutic use, Humans ; Male ; Adult ; Neoadjuvant Therapy ; Ado-Trastuzumab Emtansine

Management of hereditary hemorrhagic telangiectasia-like symptoms induced by trastuzumab emtansine in a breast cancer patient: case report.

Autori: Tyburec M Braslavsky A Serrano C a ďalší

Zdroj: Journal of chemotherapy (Florence, Italy) [J Chemother] 2025 Jul; Vol. 37 (4), pp. 383-387. Date of Electronic Publication: 2024 Jul 19.

Spôsob vydávania: Journal Article; Case Reports

Informácie o časopise: Publisher: Taylor & Francis Country of Publication: England NLM ID: 8907348 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1973-9478 (Electronic) Linking ISSN: 1120009X NLM ISO Abbreviation: J Chemother Subsets: MEDLINE

Výrazy zo slovníka MeSH: Telangiectasia, Hereditary Hemorrhagic*/chemically induced , Telangiectasia, Hereditary Hemorrhagic*/drug therapy , Breast Neoplasms*/drug therapy , Ado-Trastuzumab Emtansine*/adverse effects , Antineoplastic Agents, Immunological*/adverse effects , Antineoplastic Agents, Immunological*/therapeutic use , Maytansine*/adverse effects , Maytansine*/analogs & derivatives, Humans ; Female ; Middle Aged ; Propranolol/therapeutic use ; Trastuzumab/adverse effects

Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?

Autori: Tjalma W Teuwen LA Altintas S a ďalší

Zdroj: Breast (Edinburgh, Scotland) [Breast] 2025 Jun; Vol. 81, pp. 103885. Date of Electronic Publication: 2025 Jan 21.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE

Výrazy zo slovníka MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/metabolism , Breast Neoplasms*/pathology , Receptor, ErbB-2*/metabolism , Trastuzumab*/therapeutic use , Trastuzumab*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Agents, Immunological*/therapeutic use , Maytansine*/analogs & derivatives , Maytansine*/therapeutic use, Humans ; Female ; Neoadjuvant Therapy/methods ; Neoplasm, Residual/drug therapy ; Ado-Trastuzumab Emtansine ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/administration & dosage ; Chemotherapy, Adjuvant ; Prognosis

Drug-drug interaction between trastuzumab emtansine (T-DM1) and orally administered tacrolimus in a patient and in rats.

Autori: Nakamura T Shimada M Takabayashi M a ďalší

Zdroj: Drug metabolism and pharmacokinetics [Drug Metab Pharmacokinet] 2025 Jun; Vol. 62, pp. 101486. Date of Electronic Publication: 2025 May 03.

Spôsob vydávania: Journal Article; Case Reports

Informácie o časopise: Publisher: Elsevier Country of Publication: England NLM ID: 101164773 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1880-0920 (Electronic) Linking ISSN: 13474367 NLM ISO Abbreviation: Drug Metab Pharmacokinet Subsets: MEDLINE

Výrazy zo slovníka MeSH: Tacrolimus*/administration & dosage , Tacrolimus*/pharmacokinetics , Tacrolimus*/blood , Trastuzumab*/administration & dosage , Immunosuppressive Agents*/administration & dosage , Immunosuppressive Agents*/pharmacokinetics , Immunosuppressive Agents*/blood , Maytansine*/analogs & derivatives , Maytansine*/administration & dosage , Antineoplastic Agents, Immunological*/administration & dosage, Animals ; Ado-Trastuzumab Emtansine ; Drug Interactions ; Rats ; Administration, Oral ; Humans ; Female ; Rats, Sprague-Dawley ; Male

Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience.

Autori: Yaghoubi N Fatemi B Ahmadi R a ďalší

Zdroj: BMC health services research [BMC Health Serv Res] 2025 May 17; Vol. 25 (1), pp. 711. Date of Electronic Publication: 2025 May 17.

Spôsob vydávania: Journal Article; Comparative Study

Informácie o časopise: Publisher: BioMed Central Country of Publication: England NLM ID: 101088677 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6963 (Electronic) Linking ISSN: 14726963 NLM ISO Abbreviation: BMC Health Serv Res Subsets: MEDLINE

Výrazy zo slovníka MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Trastuzumab*/economics , Trastuzumab*/therapeutic use , Receptor, ErbB-2*/metabolism , Maytansine*/analogs & derivatives , Maytansine*/economics , Maytansine*/therapeutic use , Immunoconjugates*/economics , Immunoconjugates*/therapeutic use , Antineoplastic Agents, Immunological*/economics , Antineoplastic Agents, Immunological*/therapeutic use , Antineoplastic Agents*/economics , Antineoplastic Agents*/therapeutic use, Humans ; Cost-Benefit Analysis ; Iran ; Female ; Ado-Trastuzumab Emtansine ; Quality-Adjusted Life Years ; Neoplasm Metastasis ; Cost-Effectiveness Analysis ; Camptothecin/analogs & derivatives

Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan.

Autori: He P Gambhire D Zhou H a ďalší

Zdroj: The oncologist [Oncologist] 2025 May 08; Vol. 30 (5).

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Výrazy zo slovníka MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/mortality , Trastuzumab*/therapeutic use , Trastuzumab*/pharmacology , Trastuzumab*/administration & dosage , Immunoconjugates*/therapeutic use , Immunoconjugates*/pharmacology , Antineoplastic Agents, Immunological*/therapeutic use, Humans ; Female ; Retrospective Studies ; Middle Aged ; Aged ; Neoplasm Metastasis ; Adult ; Survival Rate ; Ado-Trastuzumab Emtansine ; Camptothecin/analogs & derivatives

Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine.

Autori: Oksuz S Kinikoglu O Ozkerim U a ďalší

Zdroj: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2025 Apr 29; Vol. 61 (5). Date of Electronic Publication: 2025 Apr 29.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE

Výrazy zo slovníka MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/mortality , Ado-Trastuzumab Emtansine*/therapeutic use , Receptor, ErbB-2*/analysis, Humans ; Female ; Retrospective Studies ; Middle Aged ; Immunohistochemistry/methods ; Adult ; Aged ; Antineoplastic Agents, Immunological/therapeutic use ; Trastuzumab/therapeutic use ; Kaplan-Meier Estimate ; Progression-Free Survival ; Treatment Outcome

Enhanced cytotoxicity of T-DM1 in HER2-low carcinomas via autophagy inhibition.

Autori: Zhang J Chang X Bai Y a ďalší

Zdroj: PloS one [PLoS One] 2025 May 02; Vol. 20 (5), pp. e0322029. Date of Electronic Publication: 2025 May 02 (Print Publication: 2025).

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Výrazy zo slovníka MeSH: Autophagy*/drug effects , Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/genetics , Trastuzumab*/pharmacology , Maytansine*/analogs & derivatives , Maytansine*/pharmacology , Antineoplastic Agents, Immunological*/pharmacology, Humans ; Ado-Trastuzumab Emtansine/pharmacology ; Cell Line, Tumor ; Signal Transduction/drug effects ; Lysosomes/metabolism ; Lysosomes/drug effects ; Proto-Oncogene Proteins c-akt/metabolism ; TOR Serine-Threonine Kinases/metabolism

Development of a mertansine-specific DNA aptamer and novel high-throughput sandwich enzyme-linked oligonucleotide assay for quantification and characterization of trastuzumab emtansine.

Autori: Yamada T Furusho A Kojima K a ďalší

Zdroj: Biosensors & bioelectronics [Biosens Bioelectron] 2025 Mar 15; Vol. 272, pp. 117108. Date of Electronic Publication: 2024 Dec 28.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: Elsevier Advanced Technology Country of Publication: England NLM ID: 9001289 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4235 (Electronic) Linking ISSN: 09565663 NLM ISO Abbreviation: Biosens Bioelectron Subsets: MEDLINE

Výrazy zo slovníka MeSH: Aptamers, Nucleotide*/chemistry , Ado-Trastuzumab Emtansine* , Biosensing Techniques*/methods , Maytansine*/analogs & derivatives, Humans ; SELEX Aptamer Technique/methods ; Trastuzumab ; Limit of Detection

Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody-Drug Radioconjugate.

Autori: Pougoue Ketchemen J Njotu FN Babeker H a ďalší

Zdroj: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Feb 17; Vol. 31 (4), pp. 685-696.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Výrazy zo slovníka MeSH: Immunoconjugates*/administration & dosage , Immunoconjugates*/chemistry , Immunoconjugates*/pharmacokinetics , Immunoconjugates*/pharmacology , Trastuzumab*/pharmacology , Trastuzumab*/administration & dosage , Receptor, ErbB-2*/antagonists & inhibitors , Receptor, ErbB-2*/metabolism , Drug Resistance, Neoplasm*/drug effects , Actinium*/chemistry , Actinium*/administration & dosage , Breast Neoplasms*/pathology , Breast Neoplasms*/drug therapy, Animals ; Humans ; Mice ; Xenograft Model Antitumor Assays ; Female ; Cell Line, Tumor ; Tissue Distribution ; Zirconium ; Radiopharmaceuticals ; Ado-Trastuzumab Emtansine

Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer.

Autori: Akyildiz A Ismayilov R Abdurrahimli N a ďalší

Zdroj: Japanese journal of clinical oncology [Jpn J Clin Oncol] 2025 Feb 04; Vol. 55 (2), pp. 100-105.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: Oxford University Press Country of Publication: England NLM ID: 0313225 Publication Model: Print Cited Medium: Internet ISSN: 1465-3621 (Electronic) Linking ISSN: 03682811 NLM ISO Abbreviation: Jpn J Clin Oncol Subsets: MEDLINE

Výrazy zo slovníka MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Receptor, ErbB-2*/metabolism , Spleen*/drug effects , Spleen*/pathology , Spleen*/diagnostic imaging , Trastuzumab*/adverse effects , Trastuzumab*/therapeutic use , Antineoplastic Agents, Immunological*/adverse effects , Antineoplastic Agents, Immunological*/therapeutic use , Maytansine*/analogs & derivatives , Maytansine*/adverse effects , Maytansine*/therapeutic use , Maytansine*/administration & dosage, Humans ; Female ; Retrospective Studies ; Middle Aged ; Ado-Trastuzumab Emtansine ; Aged ; Adult ; Organ Size/drug effects ; Neoplasm Metastasis

CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance.

Autori: Lipert BA Siemens KN Khan A a ďalší

Zdroj: Breast cancer research : BCR [Breast Cancer Res] 2025 Mar 31; Vol. 27 (1), pp. 48. Date of Electronic Publication: 2025 Mar 31.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE

Výrazy zo slovníka MeSH: Drug Resistance, Neoplasm*/genetics , Breast Neoplasms*/genetics , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/genetics , CRISPR-Cas Systems* , Ado-Trastuzumab Emtansine*/pharmacology , Antineoplastic Agents, Immunological*/pharmacology , Maytansine*/analogs & derivatives , Maytansine*/pharmacology, Humans ; Female ; Cell Line, Tumor ; Trastuzumab/pharmacology ; Gene Expression Regulation, Neoplastic/drug effects

Trastuzumab emtansine induced hyponatremia in breast cancer - A case report.

Autori: Pareeth F Babu G Mathew BS

Zdroj: Journal of cancer research and therapeutics [J Cancer Res Ther] 2025 Jan 01; Vol. 21 (1), pp. 240-242. Date of Electronic Publication: 2024 Aug 16.

Spôsob vydávania: Case Reports; Journal Article

Informácie o časopise: Publisher: Medknow Publications Country of Publication: India NLM ID: 101249598 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1998-4138 (Electronic) Linking ISSN: 19984138 NLM ISO Abbreviation: J Cancer Res Ther Subsets: MEDLINE

Výrazy zo slovníka MeSH: Antineoplastic Agents, Immunological*/adverse effects , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/complications , Hyponatremia*/chemically induced , Hyponatremia*/diagnosis , Maytansine*/adverse effects , Maytansine*/analogs & derivatives , Trastuzumab*/adverse effects, Female ; Humans ; Ado-Trastuzumab Emtansine/adverse effects ; Receptor, ErbB-2/metabolism

HER-2 SMASH.

Autori: Alandağ C Öztürk A Yulak F a ďalší

Zdroj: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 Dec 23; Vol. 95 (1), pp. 10. Date of Electronic Publication: 2024 Dec 23.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

Výrazy zo slovníka MeSH: Receptor, ErbB-2*/metabolism , Lapatinib*/pharmacology , Trastuzumab*/pharmacology , Trastuzumab*/administration & dosage, Humans ; HT29 Cells ; MCF-7 Cells ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Breast Neoplasms/metabolism ; Cell Survival/drug effects ; Up-Regulation/drug effects ; Ado-Trastuzumab Emtansine/pharmacology ; Female ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/pathology ; Colonic Neoplasms/metabolism ; Antineoplastic Agents/pharmacology ; Quinazolines/pharmacology ; Quinazolines/administration & dosage ; Antineoplastic Agents, Immunological/pharmacology ; Maytansine/analogs & derivatives ; Maytansine/pharmacology

HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor.

Autori: Zhang T Febres-Aldana CA Liu Z a ďalší

Zdroj: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 15; Vol. 30 (20), pp. 4701-4713.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Výrazy zo slovníka MeSH: Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/antagonists & inhibitors , Receptor, ErbB-2*/genetics , Desmoplastic Small Round Cell Tumor*/drug therapy , Desmoplastic Small Round Cell Tumor*/pathology , Desmoplastic Small Round Cell Tumor*/genetics , Desmoplastic Small Round Cell Tumor*/metabolism , Immunoconjugates*/pharmacology , Immunoconjugates*/therapeutic use , Xenograft Model Antitumor Assays* , Trastuzumab*/pharmacology , Trastuzumab*/therapeutic use, Humans ; Animals ; Mice ; Male ; Cell Line, Tumor ; Ado-Trastuzumab Emtansine/pharmacology ; Ado-Trastuzumab Emtansine/therapeutic use ; Female ; Apoptosis/drug effects ; Camptothecin/analogs & derivatives

Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery.

Autori: Chun SJ Kim K Kim YB a ďalší

Zdroj: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Oct; Vol. 199, pp. 110461. Date of Electronic Publication: 2024 Jul 25.

Spôsob vydávania: Journal Article; Multicenter Study

Informácie o časopise: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8407192 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0887 (Electronic) Linking ISSN: 01678140 NLM ISO Abbreviation: Radiother Oncol Subsets: MEDLINE

Výrazy zo slovníka MeSH: Breast Neoplasms*/pathology , Radiosurgery*/adverse effects , Brain Neoplasms*/secondary , Ado-Trastuzumab Emtansine*/therapeutic use , Ado-Trastuzumab Emtansine*/adverse effects , Necrosis*/etiology , Radiation Injuries*/etiology , Radiation Injuries*/pathology , Receptor, ErbB-2*/metabolism , Antineoplastic Agents, Immunological*/therapeutic use , Antineoplastic Agents, Immunological*/adverse effects, Humans ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Adult ; Trastuzumab/therapeutic use ; Trastuzumab/adverse effects ; Combined Modality Therapy